mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2021-6-106-110mrj-1237Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSСлучай регресса витилиго у пациента с псориазом и псориатическим артритом, получавшего терапию адалимумабомA case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapyhttps://orcid.org/0000-0002-0621-5518РудневаН. С.RudnevaN. S.

300053, Тула, 1-й проезд М. Расковой, 1а

1a, the 1st Raskova proezd, Tula 300053

natalya.rudneva@tularegion.ruhttps://orcid.org/0000-0001-6803-5646НатароваЭ. В.NatarovaE. V.

300053, Тула, 1-й проезд М. Расковой, 1а

1a, the 1st Raskova proezd, Tula 300053

https://orcid.org/0000-0003-3684-7310СороцкаяВ. Н.SorotskayaV. N.

300053, Тула, 1-й проезд М. Расковой, 1а

1a, the 1st Raskova proezd, Tula 300053

https://orcid.org/0000-0002-0927-4492СадунашвилиТ. Г.SadunashviliT. G.

300053, Тула, 1-й проезд М. Расковой, 1а

1a, the 1st Raskova proezd, Tula 300053

ГУЗ «Тульский областной клинический кожно-венерологический диспансер»РоссияTula Regional Clinical Skin and Venereal Diseases DispensaryRussian Federation202116122021156106110Copyright © Руднева Н.С., Натарова Э.В., Сороцкая В.Н., Садунашвили Т.Г., 20212021Руднева Н.С., Натарова Э.В., Сороцкая В.Н., Садунашвили Т.Г.Rudneva N.S., Natarova E.V., Sorotskaya V.N., Sadunashvili T.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1237

В статье рассматриваются общие звенья патогенеза аутоиммунных заболеваний кожи – псориаза и витилиго. Предлагаемые в настоящее время методы лечения витилиго не позволяют добиться значительного уменьшения или полного восстановления пигментации кожи. Применение адалимумаба в течение 6 лет у пациента, страдающего псориазом, псориатическим артритом (ПсА), витилиго и аутоиммунным тиреоидитом, позволило контролировать активность псориаза и ПсА, а также способствовало регрессу очагов депигментации.

Использования генно-инженерной биологической терапии у данной группы пациентов с целью достижения репигментации может быть перспективным.

The article discusses the common pathogenetic pathways of autoimmune skin diseases – psoriasis and vitiligo. Currently proposed treatments for vitiligo do not significantly reduce or completely restore skin pigmentation. The use of adalimumab for 6 years in a patient suffering from psoriasis, psoriatic arthritis (PsA), vitiligo and autoimmune thyroiditis made it possible to control the activity of psoriasis and PsA, and also contributed to the regression of depigmentation foci. The use of biologic disease-modifying antirheumatic drug therapy in this group of patients in order to achieve repigmentation may be promising. 

псориазпсориатический артритгенрализованное витилигоадалимумабингибитор фактора некроза опухоли αаутоиммунные заболеванияpsoriasispsoriatic arthritisgeneralized vitiligoadalimumabtumor necrosis factor α inhibitorautoimmune diseases.Статья спонсируется компанией «Эббви».This article has been supported by Abbvie.ReferencesОмельченко ВО. Летягина ЕА, Курочкина ЮД и др. Полиморфизм промоторных участков генов цитокинов в персонификации терапии генно-инженерными биологическими препаратами при ревматоидном артрите. Научно-практическая ревматология. 2019;57(3):367.Omel'chenko VO. Letyagina EA, Kurochkina YuD, et al. Polymorphism of promoter sites of cytokine genes in personification of therapy with genetically engineered biological drugs in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya. 2019; 57(3):367. (In Russ.).Безбородова ОА, Немцова ЕР, Кармакова ТА и др. Современные тенденции развития противоопухолевой генной и клеточной терапии. Research'n Practical Medicine Journal. 2019;6(Suppl):65-6.Bezborodova OA, Nemtsova ER, Karmakova TA, et al. Current trends in the development of antitumor gene and cell therapy. Research'n Practical Medicine Journal. 2019;6(Suppl):65-6. (In Russ.).Мазуров ВИ, Беляева ИБ. Патогенетическая значимость применения гуманизированного моноклонального антитела к рецептору ИЛ6-α (тоцилизумаб) в терапии иммуновоспалительных заболеваний. Медицинский совет. 2020;(8):102-12.Mazurov VI, Belyaeva IB. Pathogenetic significance of the use of a humanized monoclonal antibody to the IL6-α receptor (tocilizumab) in the treatment of immunoinflammatory diseases. Meditsinskii sovet. 2020;(8):102-12. (In Russ.).Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)» Минздрава России (версия 13 от 14.10.2021). Версия 13 14.10.2021.Temporary guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)» of the Ministry of Health of the Russian Federation (version 13 of 14.10.2021). Version 13 14.10.2021.Насонов ЕЛ, Мазуров ВИ, Лила АМ. Вопросы актуализации российских клинических рекомендаций по диагностике и лечению анкилозирующего спондилита и псориатического артрита. Научно-практическая ревматология. 2021;59(2): 229-31.Nasonov EL, Mazurov VI, Lila AM. Issues of updating of Russian clinical guidelines for the diagnosis and treatment of ankylosing spondylitis and psoriatic arthritis. Nauchnoprakticheskaya revmatologiya. 2021;59(2): 229-31. (In Russ.).https://www.rodv.ru/upload/iblock/aa2/aa20a2fc65b13df3899140167777092d.pdfhttps://www.rodv.ru/upload/iblock/aa2/aa20a2fc65b13df3899140167777092d.pdfНасонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p.Клаус В. Дерматология Фицпатрика в клинической практике. Том 1. Москва: Панфилова; 2015. С. 218-25.Klaus V. Dermatologiya Fitspatrika v klinicheskoi praktike [Fitzpatrick's Dermatology in Clinical Practice]. Volume 1. Moscow: Panfilova; 2015. P. 218-25.Мазуров ВИ, редактор. Клиническая ревматология. Руководство для врачей. 3- е издание. Москва: Е-ното; 2021.Mazurov VI, editortor. Klinicheskaya revmatologiya. Rukovodstvo dlya vrachei [Clinical rheumatology. A guide for doctors]. 3rd edition. Moscow: E-noto; 2021.Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and metaanalysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan;80(1):251-65. e19. doi: 10.1016/j.jaad.2018.06.027. Epub 2018 Jun 19.Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and metaanalysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan;80(1):251-65. e19. doi: 10.1016/j.jaad.2018.06.027. Epub 2018 Jun 19.Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan;58(1): 106-15. doi: 10.1016/j.jaad.2007.09.010. Epub 2007 Oct 23.Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan;58(1): 106-15. doi: 10.1016/j.jaad.2007.09.010. Epub 2007 Oct 23.Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008 Mar;158(3):558-66. doi: 10.1111/j.1365-2133.2007.08315.x. Epub 2007 Nov 28.Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008 Mar;158(3):558-66. doi: 10.1111/j.1365-2133.2007.08315.x. Epub 2007 Nov 28.Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279-89. doi: 10.1002/art.21306.Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279-89. doi: 10.1002/art.21306.Thaci D, Unnebrink K, Sundaram M, et al. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015 Feb; 29(2): 353-60.doi: 10.1111/jdv.12553.Thaci D, Unnebrink K, Sundaram M, et al. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015 Feb; 29(2): 353-60.doi: 10.1111/jdv.12553.Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159.Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159.Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016 May;68(5): 1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016 May;68(5): 1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.https://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2019-2020/files/%D0%9A%D0%A0%20%D0%9F%D1%81%D0%BE%D1%80%D0%B8%D0%B0%D0%B7%20%D0%B0%D1%80%D1%82%D1%80%D0%BE%D0%BF%D0%B0%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA %D0%B8%D0%B9,%202020.docxhttps://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2019-2020/files/%D0%9A%D0%A0%20%D0%9F%D1%81%D0%BE%D1%80%D0%B8%D0%B0%D0%B7%20%D0%B0%D1%80%D1%82%D1%80%D0%BE%D0%BF%D0%B0%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA %D0%B8%D0%B9,%202020.docxhttps://grls.rosminzdrav.ru/grls.aspxhttps://grls.rosminzdrav.ru/grls.aspxХобейш ММ, Шустов ДВ, Соколовский ЕВ. Гидраденит суппуративный: современные представления о патогенезе, терапии и успешный опыт лечения адалимумабом. Вестник дерматологии и венерологии. 2017;(5):70–81.Khobeish MM, Shustov DV, Sokolovskii EV. Suppurative hydradenitis: modern ideas about pathogenesis, therapy and successful experience of treatment with adalimumab. Vestnik dermatologii i venerologii. 2017;(5):70–81. (In Russ.).Круглова ЛС. Витилиго: современные взгляды на этиологию, патогенез и методы терапии. Российский журнал кожных и венерических болезней. 2016;19(4):241-4.Kruglova LS. Vitiligo: modern views on etiology, pathogenesis and methods of therapy. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2016;19(4):241-4. (In Russ.).Тальникова ЕЕ, Свенская ЮИ, Добдина АЮ и др. Витилиго: современные методы терапии. Саратовский научно-медицинский журнал. 2017;13(3):668-73.Tal'nikova EE, Svenskaya YuI, Dobdina AYu, et al. Vitiligo: modern methods of therapy. Saratovskii nauchno-meditsinskii zhurnal. 2017;13(3):668-73. (In Russ.).Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin. 2017 Apr;35(2):257-65. doi: 10.1016/j.det. 2016.11.014.Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin. 2017 Apr;35(2):257-65. doi: 10.1016/j.det. 2016.11.014.Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020 Apr 26;38:621-48. doi: 10.1146/annurevimmunol-100919-023531. Epub 2020 Feb 4.Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020 Apr 26;38:621-48. doi: 10.1146/annurevimmunol-100919-023531. Epub 2020 Feb 4.Taieb A, Alomar A, Bohm M, et al. Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Europeenne des Medecins Specialistes (UEMS) Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013 Jan;168(1):5-19. doi: 10.1111/j.1365-2133.2012.11197.x. Epub 2012 Nov 2.Taieb A, Alomar A, Bohm M, et al. Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Europeenne des Medecins Specialistes (UEMS) Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013 Jan;168(1):5-19. doi: 10.1111/j.1365-2133.2012.11197.x. Epub 2012 Nov 2.Ezzedine K, Lim HW, Suzuki T, et al. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012 May; 25(3):E1-13. doi: 10.1111/j.1755-148X.2012.00997.x.Ezzedine K, Lim HW, Suzuki T, et al. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012 May; 25(3):E1-13. doi: 10.1111/j.1755-148X.2012.00997.x.Торшина ИЕ, Зирчик АА, Булдакова МВ. Сочетанная патология: клинические наблюдения витилиго у больных псориазом. Клиническая дерматология и венерология. 2019;(18)3: 295-8.Torshina IE, Zirchik AA, Buldakova MV. Combined pathology: clinical observations of vitiligo in patients with psoriasis. Klinicheskaya dermatologiya i venerologiya. 2019;(18)3: 295-8. (In Russ.).Дубенский ВВ, Некрасова ЕГ, Муравьева ЕС и др. Псориаз у больной витилиго. Российский журнал кожных и венерических болезней. 2017;20(4):232-3.Dubenskii VV, Nekrasova EG, Murav'- eva ES, et al. Psoriasis in a patient with vitiligo. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2017;20(4):232-3. (In Russ.).Soubrier AS, Bele-Philippe P, Cortet B, et al. Treatment response, drug survival and safety of anti-tumour necrosis factor a therapy in 193 patients with psoriatic arthritis: a twelve-year «real life» experience. Joint Bone Spine. 2015 Jan;82(1):31-7. doi: 10.1016/j.jbspin.2014.08.001. Epub 2014 Oct 11.Soubrier AS, Bele-Philippe P, Cortet B, et al. Treatment response, drug survival and safety of anti-tumour necrosis factor a therapy in 193 patients with psoriatic arthritis: a twelve-year «real life» experience. Joint Bone Spine. 2015 Jan;82(1):31-7. doi: 10.1016/j.jbspin.2014.08.001. Epub 2014 Oct 11.Lopez-Ferrer A, Vilarrasa E, Gich IJ, Puig L. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol. 2013 Nov;169(5):1141-7. doi: 10.1111/bjd.12543.Lopez-Ferrer A, Vilarrasa E, Gich IJ, Puig L. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol. 2013 Nov;169(5):1141-7. doi: 10.1111/bjd.12543.Adenubiovaa E , Arenbergera P, Gkalpakiot P, et al. Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic. J Dermatolog Treat. 2018 Sep;29(6):579-82. doi: 10.1080/09546634. 2018.1425358. Epub 2018 Jan 17.Adenubiovaa E , Arenbergera P, Gkalpakiot P, et al. Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic. J Dermatolog Treat. 2018 Sep;29(6):579-82. doi: 10.1080/09546634. 2018.1425358. Epub 2018 Jan 17.Chiricozzi A, Zangrilli А, Bavetta M, et al. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. J Eur Acad Dermatol Venereol. 2017 Feb; 31(2):304-11. doi: 10.1111/jdv.13771. Epub 2016 Jun 21.Chiricozzi A, Zangrilli А, Bavetta M, et al. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. J Eur Acad Dermatol Venereol. 2017 Feb; 31(2):304-11. doi: 10.1111/jdv.13771. Epub 2016 Jun 21.Sheth VM, Guo Y, Qureshi AA. Comorbidities associated with vitiligo: a tenyear retrospective study. Dermatology. 2013; 227(4):311-5. doi: 10.1159/000354607. Epub 2013 Oct 4.Sheth VM, Guo Y, Qureshi AA. Comorbidities associated with vitiligo: a tenyear retrospective study. Dermatology. 2013; 227(4):311-5. doi: 10.1159/000354607. Epub 2013 Oct 4.Sandhu K, Kaur I, Kumar B. Psoriasis and vitiligo. J Am Acad Dermatol. 2004 Jul; 51(1):149–50. doi: 10.1016/j.jaad.2003.12.014Sandhu K, Kaur I, Kumar B. Psoriasis and vitiligo. J Am Acad Dermatol. 2004 Jul; 51(1):149–50. doi: 10.1016/j.jaad.2003.12.014Burlando M, Muracchioli A, Cozzani E, Parodi A. Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review. Case Rep Dermatol. 2021 Jul 16;13(2):372-8. doi: 10.1159/000514198. eCollection May-Aug 2021.Burlando M, Muracchioli A, Cozzani E, Parodi A. Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review. Case Rep Dermatol. 2021 Jul 16;13(2):372-8. doi: 10.1159/000514198. eCollection May-Aug 2021.Anthony N, Bourneau-martin D, Ghamrawi S, et al. Drug-induced vitiligo: A case/non-case study in vigibase®, the WHO pharmacovigilance database. Fundam Clin Pharmacol. 2020 Dec;34(6):736-42. doi: 10.1111/fcp.12558. Epub 2020 Apr 27.Anthony N, Bourneau-martin D, Ghamrawi S, et al. Drug-induced vitiligo: A case/non-case study in vigibase®, the WHO pharmacovigilance database. Fundam Clin Pharmacol. 2020 Dec;34(6):736-42. doi: 10.1111/fcp.12558. Epub 2020 Apr 27.Bae JM, Kim M, Lee HH, et al. Increased risk of vitiligo following anti-tumor necrosis factor therapy: A 10-year populationbased cohort study. J Invest Dermatol. 2018 Apr; 138(4):768-74. doi: 10.1016/j.jid.2017.11.012. Epub 2017 Nov 23.Bae JM, Kim M, Lee HH, et al. Increased risk of vitiligo following anti-tumor necrosis factor therapy: A 10-year populationbased cohort study. J Invest Dermatol. 2018 Apr; 138(4):768-74. doi: 10.1016/j.jid.2017.11.012. Epub 2017 Nov 23.Mery-Bossard L, Bagny K, Chaby G, et al. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):181-6. doi: 10.1111/jdv.13759. Epub 2016 Jun 13.Mery-Bossard L, Bagny K, Chaby G, et al. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):181-6. doi: 10.1111/jdv.13759. Epub 2016 Jun 13.

The authors declare that there are no conflicts of interest present.